NOVEL SUBSTITUTED OXAZINOISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAME

Abstract: This invention relates to novel, therapeutically active oxazinoisoquinoline derivatives of formula (I), wherein R<1> means hydrogen, a C1-4 alkyl, phenyl or phenyl-C1-4 alkyl group; one of R<2> and R<3> stands for a C1-4 alkoxy group and the other one represents a phenyl-C1-4 alkoxy group optionally substituted by a C1-4 alkyl group in the aromatic nucleus; and R<4> stands for a phenyl group optionally substituted by a C1-4 alkyl group in the aromatic nucleus and their solvates, their individual optically active and geometric isomers and mixtures of isomers as well as acid additon salts thereof. The invention further relates to pharmaceutical compositions containing the above compounds and a process for their preparation. The compounds of formula (I) are capable of inhibiting the calcium uptake to brain cells and have a protective effect in hypobaric hypoxia. Thus, they are useful in the protection from brain injuries of hypoxic origin.

Description: NOVEL SUBSTITUTED OXAZINOISOQUINOLINE DERIVATIVES, PHARMACEU¬ TICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAME This invention relates to novel, therapeutically active substituted oxazinoisoquinoline derivatives of the formula wherein R 1 means hydrogen, a Cι_4alkyl, phenyl or phenyl-Ci-4alkyl group; one of R 2 and R 3 stands for a Cι_4alkoxy group and the other one represents a phenyl-Cι_4alkoxy group optionally substituted by a Cι_4alkyl group in the aromatic nucleus; and R 4 stands for a phenyl group optionally substituted by a Cι_4alkyl group in the aromatic nucleus, and their solvates, their individual optically active and geometric isomers, mixtures of such isomers as well as acid addition salts of these compounds formed with inorganic and organic acids. Furthermore, the invention relates to pharmaceutical compositions being useful for the prevention and treatment of brain injuries; as well as to a process for preparing the compounds of the invention and to a method for treatment and prevention of brain injuries in mammals. Ischaemia-induced neurochemical alterations are related A 4824-67 MR/JG SUBSTITUTESHEET to ion fluxes through the cell membranes and subcellular me branes, respectively. However, the factor of key importan in the development of an ischaemia-induced injury is t increase in the intracellular free calcium level. The ceasi of energy supply for the cell causes the loss of the cellul calcium homeostatis. The release of potassium elicits me brane depolarization inducing the opening of the potentia dependent calcium channels. The entry of calcium to the ce partially proceeds through these potential-dependent cha nels. On the other hand, the increase in the sodium perm ability of the membrane induces an intense release excitatory amino acids (glutamate, aspartate) . The glutama released activates the receptor-dependent calcium channel permitting an additional calcium influx into the cell [ Cereb. Blood Flow Metab. £, 127 (1989)]. The influx of calcium to the cell (pre- and postsynapt calcium influx) may initiate catabolic reactions. T increased intracellular calcium level elicits reactions si nificantly influencing the functions and integrity of t cell. (Such reactions are e.g.: lipolysis, proteolysis, d composition of microtubules, excessive protein phosphoryl ation.) [Central Nervous System Trauma, Chapter 37, page 513-532 (1984)] The mechanisms playing a role in the neurotoxicity o veratrine are similar to the ischaemia-induced neurochemica changes. Veratrine significantly increases the tetrodotoxine sensitive (TTX-sensitive) sodium permeability. The membran depolarization caused by a persistent sodium influx leads t calcium influx and intracellular calcium release. In addition, veratrine-induced depolarization causes a intense release of glutamate and aspartate [Neurosci. Lett 121. 251 (1991) ;-and Brain Res. 528., 212 (1990)]. Thus, the inhibition of sodium and calcium channels ma play an important role in the mechanism of action of cerebro protective compounds. The use of the sodium channel blocke TTX proved to have an advantageous effect in the protectio against ischaemic injury (see the last two references cited Therefore, compounds diminishing the pre- or postsyna tic calcium uptake or altering the calcium sequestration the intracellular sites may bear a high therapeutic impor ance. At present, calcium antagonists are used for the trea ment of ischaemic injuries mainly on the basis of their va cular effects; however, it seems to be more and more impo tant to realize that compounds with such a mechanism action have to exert their antihypoxic, anti-ischaem effects by inhibition of the calcium influx to the neurons. Non-competitive NMDA antagonists such as MK-801 (dis cilpine) [ (+)-5-methyl-10,ll-dihydro-5H-dibenzo[a,d]cyclohe ten-5,10-imine] , which inhibit the excitatory a ino ac receptor-dependent calcium channels and, consequently, pr tect from the increase in the intracellular calcium lev [Stroke 21 (Suppl. IV), IV. 72-IV. 77 (1990); as well as Cereb. Blood Flow Metab. 9 , 127 (1989)], are of therapeut importance. Surprisingly, it has been found that the compounds the formula (I) according to the invention are capable inhibiting the calcium uptake into synaptosomeε; thus, th are suitable to protect the organism against calcium-mediat injuries (e.g. ischaemia- and hypoxia-induced injuries) a the complications arising therefrom, respectively. The synthesis of compounds of similar structure reported in Heterocycles 2_0, 1325 (1983) ; however, t pharmaceutical action of the compounds prepared is not me tioned. Substances of similar structure but with an 1-hyd oxymethyl substituent are described in the Hungarian pate specification No. 191,301; these latter compounds possess anticonvulsive effect being substantially different from th of the compounds according to the present invention. According to an other aspect of the invention, there provided a process for the preparation of compounds of t formula (I) as well as their acid addition salts, which co prises reacting an isoquinoline derivative of the formula wherein R 1 , R 2 and R 3 are as defined at formula (I) , with a isocyanate or isothiocyanate, respectively, of the formul R 4 -NCX where R 4 is as defined at formula (I) and X means oxy gen or sulfur, respectively; or with a Cι_4alkyl dithiocarba mate bearing an R 4 substituent on its nitrogen atom, where R is as defined at formula (I) , to give isoquinoline deriva tives of the formula respectively, wherein R 1 , R 2 , R 3 and R 4 are as defined at formula (I) ; then a) reacting a thus-obtained thiocarbamoylisoquinoline derivative of the formula (IV), wherein R 1 , R 2 , R 3 and R 4 are as defined at formula (I) , with a Cι_4alkyl halide; or b) treating a thus-obtained carbamoylisoquinoline deri- vative of the formula (III), wherein R 1 , R 2 , R 3 and R 4 are as defined at formula (I) , with a dehydrating agent; then, if desired, reacting the thus-obtained compoun of the formula (I), wherein R 1 , R 2 , R 3 and R 4 are as define at formula (I) , with an acid to give an acid addition salt; and/or treating a compound of the formula (I), wherein R 1 , R 2 , R 3 and R 4 are as defined at formula (I) , obtained in the for of its acid addition salt, with a base to liberate the fre basic form. The isoquinoline derivatives of the formula (II) use as starting substances are also novel compounds, which may b prepared from the known 3,4-dihydroisoquinoline derivative of the formula For this purpose, firstly a 3,4-dihydroisoquinoline derivative of formula (V) , wherein R 1 , R 2 and R 3 are as defined at formula (I) , is reacted with formaldehyde or its hydrate or a trimeric or polymeric derivative thereof, pre¬ ferably in the presence of a base, then the 1-hydroxy-ethyl- 3,4-dihydroisoquinoline derivative of the formula obtained, wherein R 1 , R 2 and R 3 are as defined at formula (I) , is reduced. When preparing the compounds of the formula (VI) alka- line metal alkoxides and hydroxides may be used as bases; sodium methoxide, sodium ethoxide and sodium hydroxide are preferably used. According to a preferred embodiment 2.5 moles of para- formaldehyde in methanolic suspension are added to a solution of 1 mole of 3,4-dihydroisoquinoline derivative of formula (V) in methanol, and subsequently a freshly prepared ethano- lic sodium ethoxide solution is added in an amount sufficient to dissolve the suspension. Then the reaction mixture is stirred at room temperature for about 6 hours and evaporated. The appropriately substituted l-hydroxyethyl-3,4-dihydroiso- quinoline derivative of the formula (VI) is obtained as an evaporation residue. The subsequent reduction may be carried out by using a complex metal hydride or catalytic hydrogenation. Sodium borohydride dissolved in an alkanol or aqueous alkanol medium may preferably be used as a complex metal hydride. The cata¬ lytic hydrogenation may advantageously performed by using a palladium-on-carbon or platinum-on-carbon catalyst. In the latter case, ' alkanol is preferably used as solvent. In the course of the reduction mixtures of diastereo- mers are formed, the isomer ratio of which depends on the reducing agent. The components of these mixtures can be separated by using well known methods, preferably fractional crystallization. If desired, the compounds of the formula (II) obtained may be converted to their salts. The reduction step is preferably carried out in such a way that, after dissolving 1 mole of a l-hydroxyethyl-3,4-di- hydroisoquinoline derivative of the formula (VI) in methanol, about 4 moles of sodium borohydride are added to the solution in small portions while cooling with ice. After the termina¬ tion of the reaction the mixture is evaporated to give an appropriately substituted isoquinoline derivative of formula (II). The calcium uptake-inhibitory effect of the compounds of the formula (I) according to the invention was studied on synaptosomes prepared from rat brain by using a method des- cribed in J. Neurochem. 3_2, 700 (1982) in the following manner. Wistar rats weighing 180 to 200 g were decapitated and the brains were collected in ice-cold physiological saline, the cortex was removed and purified from the white matter. The tissue was homogenized by a glass-teflon potter in 10 volumes of a saccharose solution of 0.32 moles/litre concen¬ tration. The homogenate was centrifuged at 1000 x g in a Ja- netzki K-70 centrifuge at 4°C for 10 minutes, the supernatant was centrifuged at 12000 x g in a Hitachi CR-26H centrifuge at 4°C for 20 minutes. The sediment was suspended in a saccharose solution of 0.32 moles/litre concentration, then the protein content of the preparation was adjusted to 20 mg/ml. Components of the solution used for incubation were as follows: a) For investigation of the potassium-stimulated cal¬ cium uptake: 112 mmoles/1 of sodium chloride, 5 mmoles/1 of potassium chloride, 1.3 mmoles/1 of magnesium chloride, 1.2 mmoles/1 of sodium dihydrogen phosphate, 1.2 mmoles/1 of cal¬ cium chloride, 10 mmoles/1 of glucose and 20 mmoles/1 of tri- (hydroxymethyl)aminomethane (TRIS) ; b) For investigation of the veratrine-stimulated cal¬ cium uptake: 132 mmoles/1 of sodium chloride, 5 mmoles/1 of potassium chloride, 1.3 mmoles/1 of magnesium chloride, 1.2 mmoles/1 of sodium dihydrogen phosphate, 1.2 mmoles/1 of cal¬ cium chloride, 10 mmoles/1 of glucose and 20 mmoles/1 of TRIS. Incubation solution was saturated with oxygen contain- ing 5% by volume of carbon dioxide until reached a pH value of 7.4. The test compounds and the synaptosome preparation in an amount corresponding to 1 mg of protein were added into the incubation solution. The final volume of incubation was 1 ml. The samples were pre-incubated at 37°C for 20 minutes. The calcium uptake was initiated by addition of a 5 CaCl solution of 2.8 kBq (75 nCi) activity. Potassium chloride was used in a concentration of 60 mmoles/1 for th investigation of potassium-stimulated calcium uptake; sodiu chloride was added in the same concentration to the contro samples. Veratrine was used in a concentration of 20 μmoles/ for investigating the veratrine-stimulated calcium uptake. The incubation time was 20 seconds. The reaction stoppe by adding 5 ml of a stopping solution containing 120 mmoles/ of sodium chloride, 5 mmoles/1 of potassium chloride, mmoles/1 of EGTA [ethylene glycol bis(β-aminoethyl)ether N,N,N' ,N'-tetraacetic acid] and 20 mmoles/1 of TRIS (pH 7.4) The samples were filtered through a Whatman GF/C filte and washed twice with 5-5 ml of a washing solution containin 132 mmoles/1 of sodium chloride, 5 mmoles/1 of potassiu chloride, 1.3 mmoles/1 of magnesium chloride, 1.2 mmoles/1 o calcium chloride and 20 mmoles/1 of TRIS (pH 7.4) After placing the filter disks in glass cuvets, 10 m of scintillation cocktail [containing 1000 ml of toluene, 40 ml of abs. ethanol, 10 ml of dioxane, 6 g of 2,5-diphenyl oxazole and 0.15 g of l,4-bis(5-phenyl-2-oxazolyl)benzene] a d the radioactivity of the samples was measured by using a 1219 Rackbeta type liquid scintillation spectrophotomete (product of LKB Wallace Company) . The IC5 0 values shown in Table 1 were determined by measuring the concentration-effect relation of the compounds. Table 1 Inhibition of the stimulated calcium uptake Inhibition of Name/code No. Potassium-stimulated Veratrine-stimulated of compound Ca uptake Ca uptake - IC5 0 (μmole/1) 1507136 23.9 0.29 ni odipine 208.0 6.7 cinnarizine 71.6 1.0 flunarizine 22.6 1.3 Note: The compound No. 1507136 is 9-benzyloxy-10-meth- oxy-4-(p-tolylimino)-1,6,7,llb-tetrahydro-2H,4H-1,3-oxazino- [4,3-a]isoquinoline hydrochloride Nimopidine [isopropyl 2-methoxyethyl l,4-dihydro-2,6 dimethyl-4-(m-nitrophenyl)-3 ,5-pyridinedicarboxylate] , cinna rizine [l-trans-cinnamyl-4-(diphenylmethyl)piperazine] a well as flunarizine [l-cinnamyl-4-[bis(4-fluorophenyl) methyl]-piperazine] were used as reference drugs. It is obvious from the data of Table 1 that the com pounds according to the invention possess a calcium uptake inhibitory effect. In comparison to nimodipine, their effec on the calcium uptake induced by either potassium or vera trine is much stronger. The potassium-induced calcium uptake inhibitory effect of compound No. 1507136 exceeds that o cinnarizine. The substance tested blocked also the veratrine induced calcium uptake to a higher degree than flunarizin did. The antihypoxic effect of the target compounds wa studied on genetically hypertensive rats (SHR) , which ar particularly sensitive to hypoxic insults. Male rats weighin 210 to 230 g each were used for these experiments. The hypobaric hypoxia test The experimental animals were placed in pairs in desiccator of 6 litres volume one hour after administratio of the compound to be tested. The pressure in the desiccato was decreased to 22.66 kPa (170 mmHg) during 20 seconds. Th time elapsing from this point until the last respirator movement was measured. An aminal was considered to be pro tected when its survival time was by 30% longer in compariso with the control group. The ED 50 value (i.e. the dose bein effective in 50% of the animals) together with the corre sponding fiducial limits was calculated by using the probi analysis from the percentage of the animals protected. Table 2 The hypobaric hypoxia test Name/code No. ED50 of compounds (mg/kg) 1507136 8.0 nimodipine 8.0 flunarizine 50.0 It can be stated from the results shown in Table 2 tha the effect of compounds of the present invention is equal t that of nimodipine under severe hypoxic conditions (hypobari hypoxia) and is significantly better than that of flunari zine. Based on the above investigations the compounds accordin to the invention can therapeutically be used mainly agains brain injuries of severely hypoxic origin. The compounds of the invention can be used orally o parenterally either alone or in the form of pharmaceutica compositions. These compositions may be mainly tablets, cap sules, powders, syrups, injectable solutions or supposi tories. The daily doses of the active compounds are betwee 0.1 and 50 mg/kg of body weight; however, this limit valu may be exceeded depending on the severity of the pathologica state to be treated since the toxicity of compounds of th invention is low (e.g. the oral LD50 value of the compoun No. 1507136 is 1400 mg/kg of body weight) . The daily dose o the active compound may be administered once or in subdose to the patient to be treated. The invention also relates to a method for preventio and treatment of brain injuries of hypoxic origin. Thi method comprises administering a therapeutically effectiv amount of an active agent of the formula (I) or a pharma ceutically acceptable acid addition salt thereof to th patient. The invention is illustrated in detail by the aid of the following non-limiting Examples. The identity of iden¬ tical products prepared by various methods was confirmed by their IR spectra and mixed melting points. Example 1 A mixture containing 0.01 mole of a 1-(2-hydroxy- ethyl)-6,7-disubstituted-l,2,3,4-tetrahydroisoquinoline of formula (II) and 0.01 mole of an isothiocyanate of formula R 4 -CNS in 50 ml of benzene is refluxed under nitrogen for 1 hour. After evaporation of the solvent the corresponding iso¬ quinoline derivative of formula (IV) is obtained in crystal¬ line form in a yield of 85-94%. Example 2 A mixture of 0.01 mole of a l-(2-hydroxyethyl)-6,7-di- substituted-l,2,3,4-tetrahydroisoquinoline, 0.01 mole of a Cι_4alkyl dithiocarbamate bearing an R 4 substituent on the nitrogen atom and 50 ml of ethanol is refluxed for 3-4 hours. After evaporating the solvents, the corresponding compound of the formula (IV) is obtained as crystals in a yield of 76- 92%. The following compounds were prepared by following the processes described in Examples 1 and 2: 6-benzyloxy-l-(2-hydroxyethyl)-7-methoxy-2-(p_-tolyl- thiocarbamoyl)-l,2,3,4-tetrahydroisoquinoline, m.p. : 181- 182°C (after recrystallization from methanol); 7-benzyloxy-l-(2-hydroxyethyl)-6-methoxy-2-(p-tolyl- thiocarbamoyl)-1,2,3,4-tetrahydroisoquinoline, m.p.: 121- 123°C (after recrystallization from ethanol) . Example 3 A mixture corresponding 0.01 mole of a l-(2-hydroxy- ethyl)-6,7-disubstituted-l,2,3,4-tetrahydroisoquinoline of the formula (II) and 0.01 mole of an isocyanate of the for¬ mula R 4 -CNO in 50 ml of benzene is refluxed for 1 hour. After evaporating the solvent the corresponding compound of the formula (III) is obtained as crystals in a yield of 85-92%. Example 4 After adding 1.7 g (0.012 mole) of methyl iodide and ml of methanol to 0.01 mole of a l-(2-hydroxyethyl)-6,7-d substituted-2-thiocarbamoyl-l,2,3,4-tetrahydroisoquinoline the formula (IV) , the reaction mixture is stirred for 3 hours, then the solvent is evaporated. The residue is stirr with 20 ml of methanolic potassium hydroxide solution of moles/litre concentration until the complete removal methyl mercaptan. After evaporating the mixture to dryness little water is added to the residue and then extracted times with 20 ml of chloroform each. After combining t extracts are dried and evaporated to give the correspondi oxazine derivative of the formula (I) in a yield of about 7 86%. In some cases the working-up of the reaction mixture modified: when the product precipitates in a crystalline fo after evaporation to dryness and addition of a little wate it is separated by filtration. Example 5 After adding 10 ml of thionyl chloride to 0.005 mol of 1-(2-hydroxyethyl)-6,7-disubstituted-2-carbamoyl-l,2,3, tetrahydroisoquinoline of the formula (III) prepared as de cribed in Example 3, the reaction mixture is allowed to sta overnight. After evaporating the excess of thionyl chlorid the residue is dissolved in a little water under coolin neutralized by adding sodium hydrogen carbonate, th extracted with chloroform. After drying and evaporating t extract, the corresponding oxazine derivative of the formul (I) is obtained in crystalline form in a yield of about 65 70%. Example 6 After adding 10 ml of phosphorous oxychloride to 0.00 moles of a l-(2-hydroxyethyl)-6,7-disubstituted-2-carbamoyl 1,2,3,4-tetrahydroisoquinoline of the formula (III) prepare as described in Example 3, the process described in Example is followed to obtain a yield of 58%. By reacting with an acid, the compounds of the formula (I) obtained in the form of free base can be converted to their acid addition salts. The hydrochloride may preferably be formed by reacting the free base with a solution of hydro- gen chloride in ethanol. The following compounds were prepared by following the process described in Examples 4-6: 9-benzyloxy-10-methoxy-4-(p-tolylimino)-1,6,7,11b- tetrahydro-2H,4H-1,3-oxazino[4,3-a]isoquinoline hydrochlor- ide, m.p.: 155-158°C (after recrystallization from a mixture of ethanol and ether) ; 10-benzyloxy-9-methoxy-4-(p-tolylimino)-1,6,7,11b- tetrahydro-2H,4H-1,3-oxazino[4,3-a]isoquinoline hydrochlor¬ ide, m.p.: 139-143°C (after recrystallization from a mixture of ethanol and ether) . Example 7 Preparation of tablets containing 5 or 50 mg, respect¬ ively, of active ingredient each Tablets with a weight of 150 mg or 300 mg each, respectively, containing the components listed hereinafter are prepared by using known methods of wet granulation and compression. Components Amounts (mg) in the tablet containing 5 mg of 50 mg of active agent active agent Active ingredient 5 50 Gelatine 3 Polyvidone (polyvinyl- pyrrolidone) - 6 Magnesium stearate 2 3 Talc 5 9 Potatoe starch 40 84 Lactose 95 148 Total: 150 mg 300 mg

Claims: Claims: 1. Novel substituted oxazinoisoquinoline derivatives the formula wherein R 1 means hydrogen, a C _4alkyl, phenyl or phenyl-C _4al group; one of R 2 and R 3 stands for a Cι_ alkoxy group and the oth one represents a phenyl-C ___4alkoxy group optional substituted by a Cι_4alkyl group in the aromat nucleus; and R 4 stands for a phenyl group optionally substituted by C _ alkyl group in the aromatic nucleus and their solvates, their individual optically active a geometric isomers and mixtures of such isomers as well acid addition salts thereof. 2. 10-Benzyloxy-9-methoxy-4-(4-tolylimino)-1,6,7,11b- tetrahydro-2H,4H-l,3-oxazino[4,3-a]isoquinoline and ac addition salts thereof. 3. 9-Benzyloxy-10-methoxy-4-(4-tolylimino)-1,6,7,11b- tetrahydro-2H,4H-l,3-oxazino[4,3-a]isoquinoline and ac addition salts thereof. 4. A pharmaceutical composition, which comprises active ingredient a therapeutically effective amount of substituted oxazino-isoquinoline derivative of the formu (I) r wherein R 1 , R 2 , R 3 and R 4 are as defined in claim 1, admixture with usual adjuvants such as carriers, dilutin stabilizing, osmotic pressure-influencing, pH-adjustin savouring, aromatizing and formulation-assisting agents. SUBSTITUTESHEET 5. A process for the preparation of novel oxazino-iso quinoline derivatives of the formula wherein R 1 means hydrogen, a Ci-.-^alkyl, phenyl or phenyl-C 1 _4alky group; one of R 2 and R 3 stands for a Cι_4alkoxy group and the othe one represents a phenyl-C _4alkoxy group optionall substituted by a Cι_4alkyl group in the aromati nucleus; and R 4 stands for a phenyl group optionally substituted by C _4alkyl group in the aromatic nucleus and their solvates, their individual optically active an geometric isomers and mixtures of isomers as well as aci addition salts thereof, which comprises reacting an isoquinoline derivative of the formula wherein R 1 , R 2 and R 3 are as defined at formula (I), with a isocyanate or isothiocyanate, respectively, of the formul R 4 -NCX where R 4 is as defined at formula (I) and X means oxy gen or sulfur, respectively; or with a Cι_4alkyl dithiocarba mate bearing an R 4 substituent on its nitrogen atom, where R is as defined at formula (I), to give isoquinoline deriva tives of the formula JSUBSTITUTE SHEET or respectively, wherein R 1 , R 2 , R 3 and R 4 are as defined formula (I) ; then ' a) reacting a thus-obtained thiocarbamoylisoquinoli derivative of the formula (IV), wherein R 1 , R 2 , R 3 and R 4 a as defined at formula (I) , with a Cι_4alkyl halide; or b) treating a thus-obtained carbamoylisoquinoline deri vative of the formula (III), wherein R 1 , R 2 , R 3 and R 4 are a defined at formula (I) , with a dehydrating agent; then, if desired, reacting the thus-obtained compoun of the formula (I), wherein R 1 , R 2 , R 3 and R 4 are as define at formula (I) , with an acid to give an acid addition salt and/or treating a compound of the formula (I) , wherein R , R 2 R 3 and R 4 are as defined at formula (I) , obtained in the for of its acid addition salt, with a base to liberate the fre basic form. 6. A process as claimed in process a) of claim 5, whic comprises using methyl iodide as a Cι_4alkyl halide. 7. A process as claimed in process b) of claim 5, whic comprises using thionyl chloride or phosphorus oxychloride a dehydrating agent. 8. Method for inhibiting the uptake of calcium to th brain of mammals, characterized by administering to the mam mal, including human, to be treated a therapeutically effect ive amount of an oxazinoisoquinoline derivative of the for mula (I), wherein R 1 , R 2 , R 3 and R 4 are as defined in clai 1, alone or in the form of a pharmaceutical composition.

Inventors: ARVA JUDIT, BERNATH GABOR, BODO MIHALY, CSOMOR KATALIN, FUELOEP FERENC, GERE ANIKO, HUBER IMRE, KARPATI EGON, KISS BELA, KOBOR JENOE, LAPIS ERZSEBET, LASZY JUDIT, LAZAR LASZLO, PALOSI EVA, SARKADI ADAM, SZABO SANDOR, SZENTIRMAI ZSOLT, SZOMBATHELYI ZSOLT, SZPORNY LASZLO, ARVA, JUDIT, BERNATH, GABOR, BODO, MIHALY, CSOMOR, KATALIN, FUELOEP, FERENC, GERE, ANIKO, HUBER, IMRE, KARPATI, EGON, KISS, BELA, KOBOR, JENOE, LAPIS, ERZSEBET, LASZY, JUDIT, LAZAR, LASZLO, PALOSI, EVA, SARKADI, ADAM, SZABO, SANDOR, SZENTIRMAI, ZSOLT, SZOMBATHELYI, ZSOLT, SZPORNY, LASZLO
Applicants: RICHTER GEDEON VEGYESZET, RICHTER GEDEON VEGYESZETI GYAR RT.
Application year: 1992
Main classification: C07D221
IPC codes: A61K31, A61P3, A61P9, A61P25, C07D217, C07D498